Market Update (NYSE:BMY): New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma

[Business Wire] – Bristol-Myers Squibb Company today announced new long-term data of Opdivo in treatment-naïve BRAF wild-type advanced melanoma from CheckMate -066. In the trial, Opdivo continued to demonstrate superior overall survival versus . . . → Read More: Market Update (NYSE:BMY): New Long-Term Data on Opdivo and the Opdivo + Yervoy Regimen Shows Survival Benefit Across Lines of Therapy in Advanced Melanoma Similar Articles: Company Update (NYSE:BMY): Bristol-Myers Squibb to Present New Data for Opdivo (nivolumab) in Advanced Melanoma, as Monotherapy and in Combination with Yervoy (ipilimumab), at the Society for Melanoma Research 2015 International Congress Stock Update (NYSE:BMY): Opdivo (nivolumab) Demonstrates Superior Overall Survival in a Phase 3 Trial Compared to Standard of Care in Patients with Previously Treated Advanced Renal Cell Carcinoma Company Update: Bristol-Myers Squibb Company (NYSE:BMY) – New Cohorts from CheckMate -012 Assess Optimal Dosing of Opdivo+Yervoy in the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer